Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review

详细信息    查看全文

• 作者：Claudia Marchetti^a ; ^b ; Rebecca Kristeleit^a ; Mary McCormack^c ; Tim Mould^d ; Adeola Olaitan^d ; Martin Widschwendter^d ; Nicola MacDonald^d ; Jonathan A Ledermann^a ; ^{j.ledermann@ucl.ac.uk}
• 关键词：Advanced ovarian cancer ; Surgery ; Chemotherapy ; Neoadjuvant ; Debulking ; Carboplatin ; Paclitaxel
• 刊名：Gynecologic Oncology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：144
• 期：1
• 页码：57-60
• 全文大小：250 K
• 卷排序：144

文摘

Debulking surgery is not feasible for up to 20% of patients. Chemotherapy alone can allow reasonable disease control in women unsuitable for IDS. Carboplatin plus paclitaxel should be used when possible.